Abstract

Introduction: Facial hyperpigmentation, including melasma and post-inflammatory hyperpigmentation, is a common condition with significant psychosocial impact, particularly in individuals with Fitzpatrick phototypes III–VI. Current treatments, photoprotection, depigmenting agents, peels, and lasers may be limited by adverse effects and recurrence. A novel molecule, 2-mercaptonicotinoyl glycine (2-MNG) reduces pigmentation by trapping melanin precursors while preserving melanocyte viability. This study evaluated the efficacy of a 2-MNG-containing serum (MB3 serum) on hyperpigmentation disorders in subjects of any phototype. Material and methods: This prospective observational study, conducted in Morocco evaluated MB3 serum in 522 subjects aged 17–75 years with mild-to-moderate hyperpigmentation. Applied once or twice daily for three months alongside broad spectrum SPF50+/UVA photoprotection, efficacy was assessed through clinical evaluations, patient-reported outcomes, stigmatisation (PUSH-D), compliance, satisfaction, and local tolerance. Results: Among 522 subjects (mean age 35.3 years; 85.4% women), melasma (44.8%) and post-inflammatory hyperpigmentation (49.6%) were the most common hyperpigmentation disorders. After 3 months of MB3 serum use, over 83% showed improvement in hyperpigmentation severity, visibility, and associated bother. Perceived stigma decreased by approximately 60% (p<0.001). Treatment compliance, satisfaction, recommendation rates, and local tolerance were exceptionally high, supporting the effectiveness and acceptability of MB3 serum in routine practice . Conclusion: Results from this study suggest that MB3 serum is an effective and well- tolerated treatment for facial hyperpigmentation, significantly improving pigmentation, reducing disease burden and stigma, and achieving high patient satisfaction in routine practice.

Keywords

hyperpigmentation disorders, melasma, post-inflammatory hyperpigmentation, 2-MNG, 2-mercaptonicotinoyl glycine